Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver
Lymphoma highlights from EHA 2016
Highlights from the 2016 European Multiple Myeloma Academy (EMMA) and overview of EMMA 2017
Jesús San Miguel
Panel discussion on new technologies in lymphoma - the applications of circulating tumor DNA
Ash Alizadeh et al.
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML